Navigation Links
Vical to Present at BIO CEO and Investor Conference
Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that Vijay Samant, the company's President and Chief Executive Officer, will present a company overview at 3:30 p.m. EST on Monday, February 11, at the Biotechnology Industry Organization (BIO) CEO and Investor Conference (New York - February 11-13).

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hollywood On the Hill - A Red Carpet Event on Capitol Hill Raises Awareness for Cervical Cancer Prevention and HPV-Related Technologies
2. National Cervical Cancer Coalition (NCCC) State Chapters to Provide Parents With Educational Forum to Discuss Cervical Cancer and HPV Vaccines
3. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
4. National Cervical Cancer Coalition Stresses Importance of Screening and Prevention During January Cervical Health Awareness Month
5. Study determines costs of breast and cervical cancer detection among low-income women
6. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine
7. Vical Expands Clinical Testing of DNA Vaccine Against H5N1 Pandemic Influenza
8. Post-treatment PET scans can reassure cervical cancer patients
9. PET Scans Can Spot Cervical Cancers Return
10. Pill Poses Little Cervical Cancer Risk
11. Study Finds New Version of QIAGENs HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Rockville, MD (PRWEB) , ... December 09, 2016 ... ... need for counseling and aural rehabilitation—provided by audiologists—to remain a critical part of ... U.S. Food and Drug Administration (FDA) announced this week that, starting ...
(Date:12/9/2016)... ... December 09, 2016 , ... Cellairis is a worldwide mobile ... on iPhone , iPad and Samsung Galaxy devices with premium parts ... in order to maximize convenience and accessibility for customers. While customers do their shopping, ...
(Date:12/9/2016)... ... , ... "I have gout, and I wanted to treat it naturally," said ... to relieve gout and pain caused by varicose veins. I drank it every morning ... relieved what VA doctors called the worst sinusitis case they'd seen and relieved gas, ...
(Date:12/9/2016)... CA (PRWEB) , ... December 09, 2016 , ... ... young adults, celebrated its 10th anniversary with the grand opening of the Sober ... The successful event spanned two days, December 2-3, and was attended by an ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... Mediaplanet today ... for organ transplantation while encouraging readers to sign up as an organ donor for ... organ transplant. , An organ donor can save up to 8 saves through ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento de ... refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
Breaking Medicine Technology: